Lindström, Ulf http://orcid.org/0000-0002-2250-9348
Olofsson, Tor
Wedrén, Sara
Qirjazo, Ilia
Askling, Johan
Funding for this research was provided by:
Karolinska Institutet (NA)
Article History
Received: 15 February 2019
Accepted: 7 May 2019
First Online: 28 May 2019
Ethics approval and consent to participate
: The ethical review board in Stockholm, Sweden, approved the study (dnr:2011/29-31/1). Individual patient consent was not required.
: Not applicable.
: UL, SW, IQ and TO declare that they have no competing interests. JA has entered into agreements with Abbvie, BMS, Lilly, Merck, Pfizer, Roche, Samsung Bioepis, and UCB, mainly for safety monitoring via the Swedish ARTIS system (see below), and received a travel reimbursement from Novartis. Karolinska Institutet has received remuneration for JA’s participation in meetings arranged by Pfizer and by Lilly.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.